| 26.8 0.05 (0.19%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.32 | 1-year : | 33.14 |
| Resists | First : | 27.67 | Second : | 28.37 |
| Pivot price | 27.26  |
|||
| Supports | First : | 26.54 | Second : | 22.08 |
| MAs | MA(5) : | 26.74 |
MA(20) : | 27.35 |
| MA(100) : | 21.52 |
MA(250) : | 22.68 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 9.5 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 38.59 | Low : | 13.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STAA ] has closed above bottom band by 23.7%. Bollinger Bands are 55.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.94 - 27.13 | 27.13 - 27.28 |
| Low: | 26.34 - 26.54 | 26.54 - 26.7 |
| Close: | 26.54 - 26.85 | 26.85 - 27.09 |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Fri, 26 Sep 2025
STAAR Surgical (STAA) Proposes $28 All-Cash Merger with Alcon - GuruFocus
Fri, 26 Sep 2025
59% Premium at $28 Per Share: STAAR Surgical Board Champions Alcon Merger as China Sales Decline Continues - Stock Titan
Fri, 26 Sep 2025
Assenagon Asset Management S.A. Acquires 111,686 Shares of STAAR Surgical Company $STAA - MarketBeat
Fri, 26 Sep 2025
3 Reasons to Avoid STAA and 1 Stock to Buy Instead - The Globe and Mail
Thu, 25 Sep 2025
Strs Ohio Invests $190,000 in STAAR Surgical Company $STAA - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 49 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 110.6 (%) |
| Shares Short | 3,990 (K) |
| Shares Short P.Month | 6,450 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.82 |
| Profit Margin | -42.5 % |
| Operating Margin | -55.7 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | -55.3 % |
| Gross Profit (p.s.) | 3.26 |
| Sales Per Share | 4.54 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -13.89 |
| PEG Ratio | 0 |
| Price to Book value | 3.92 |
| Price to Sales | 5.89 |
| Price to Cash Flow | -46.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|